drugset
drugset / Trial / NCT02692040

Study of the Gut Hormone Analogue G3215 in Adult Subjects

NCT02692040 ↗

Phase 1 Completed 90 enrolled Imperial College London Covance · collabMedical Research Council · collab
RandomizedSingle-groupDouble-blindTreatment

Summary

A randomised, placebo controlled Phase I study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of G3215 in adult subjects.

Timeline

Start
2015-01
Primary completion
2019-01
Completion
2019-01

Drugs

EvaluationDrugModalityDoseRoute
Subject G3215 Protein / enzyme biologic 0.1 mg Subcutaneous
Subject G3215 Protein / enzyme biologic 0.5 mg Subcutaneous
Subject G3215 Protein / enzyme biologic 1.5 mg Subcutaneous
Subject G3215 Protein / enzyme biologic 3.2 mg Subcutaneous
Subject G3215 Protein / enzyme biologic 4 mg Subcutaneous
Subject G3215 Protein / enzyme biologic 8 mg Subcutaneous
Subject G3215 Protein / enzyme biologic 10 mg Subcutaneous
Subject G3215 Protein / enzyme biologic 12 mg Subcutaneous
Subject G3215 Protein / enzyme biologic 16 mg Subcutaneous
Subject G3215 Protein / enzyme biologic 24 mg Subcutaneous
Subject G3215 Protein / enzyme biologic 32 mg Subcutaneous
Subject G3215 Protein / enzyme biologic 48 mg Subcutaneous

Indications

diabetes mellitus obesity disorder